New drug for fatty liver disease passes first safety check in healthy people
NCT ID NCT06716905
First seen Nov 17, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This early-stage study tested the safety and how the body processes a new drug called ACT500 in 72 healthy Chinese adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was not to treat any disease, but to gather important safety information and see how the drug moves through the body before testing it in people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.